Published in PLoS One on January 27, 2014
Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy. Bioinformatics (2014) 0.82
Prediction of disease-gene-drug relationships following a differential network analysis. Cell Death Dis (2016) 0.76
Repositioning of a cyclin-dependent kinase inhibitor GW8510 as a ribonucleotide reductase M2 inhibitor to treat human colorectal cancer. Cell Death Discov (2016) 0.76
Quantitative Identification of Compound-Dependent On-Modules and Differential Allosteric Modules From Homologous Ischemic Networks. CPT Pharmacometrics Syst Pharmacol (2016) 0.75
Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. BMJ Open (2016) 0.75
DeSigN: connecting gene expression with therapeutics for drug repurposing and development. BMC Genomics (2017) 0.75
A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles Using Pathway-Drug Network. Biomed Res Int (2016) 0.75
A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer. BMC Med Genomics (2016) 0.75
Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet (2000) 336.52
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc (2009) 137.99
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Human Protein Reference Database--2009 update. Nucleic Acids Res (2008) 21.25
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics (2006) 11.33
Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol (2008) 8.51
New uses for old drugs. Nature (2007) 5.86
Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med (2011) 5.77
Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med (2011) 5.30
Transcriptome profile of human colorectal adenomas. Mol Cancer Res (2007) 3.82
Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov (2006) 3.40
Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res (2011) 3.05
A network view of disease and compound screening. Nat Rev Drug Discov (2009) 2.90
A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf (2006) 2.69
Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal (2009) 2.57
Network analyses in systems pharmacology. Bioinformatics (2009) 2.55
Cancer: a Systems Biology disease. Biosystems (2006) 2.29
Cancer systems biology: a network modeling perspective. Carcinogenesis (2009) 2.22
Why is cancer drug discovery so difficult? Nat Rev Drug Discov (2006) 1.90
Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69
Thapsigargin, a histamine secretagogue, is a non-12-O-tetradecanoylphorbol-13-acetate (TPA) type tumor promoter in two-stage mouse skin carcinogenesis. J Cancer Res Clin Oncol (1986) 1.61
Use of thapsigargin to study Ca2+ homeostasis in cardiac cells. Biosci Rep (1995) 1.28
A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood (1958) 1.23
Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One (2009) 1.18
Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells. Mol Pharmacol (2008) 1.18
Drug profiling: knowing where it hits. Drug Discov Today (2010) 1.18
Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res (1988) 1.15
Drug repurposing: far beyond new targets for old drugs. AAPS J (2012) 1.09
Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem. Drugs Aging (2012) 1.08
Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer. PLoS Comput Biol (2012) 1.06
Ginkgo biloba extracts and cancer: a research area in its infancy. Fundam Clin Pharmacol (2003) 1.00
Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells. Prostate (2000) 0.98
Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin. Prostate (1997) 0.98
Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD-1 and suppression by N-acetyl-L-cysteine. Cancer Sci (2003) 0.98
Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer's disease. Pharmacopsychiatry (2003) 0.97
Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma. PLoS One (2011) 0.96
Screening for epigenetically masked genes in colorectal cancer Using 5-Aza-2'-deoxycytidine, microarray and gene expression profile. Cancer Genomics Proteomics (2012) 0.96
Genotoxicity and carcinogenicity studies of antihypertensive agents. Mutat Res (2006) 0.93
Ginkgo biloba extract in Alzheimer's disease: from action mechanisms to medical practice. Int J Mol Sci (2010) 0.92
Differential effects of L-buthionine sulfoximine and ethacrynic acid on glutathione levels and mitochondrial function in PC12 cells. Neurosci Lett (1999) 0.92
Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Saf (2007) 0.88
An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors. PLoS One (2011) 0.87
Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. J Pharmacol Exp Ther (1994) 0.85
Biological investigations of 6-azathymine, a thymine analog. Cancer Res (1954) 0.83
Pharmacological action and mechanisms of ginkgolide B. Chin Med J (Engl) (2007) 0.83
Mechanisms of resistance and adaptation to thapsigargin in androgen-independent prostate cancer PC3 and DU145 cells. Arch Biochem Biophys (2007) 0.81
Inhibitory effects of extracellular Mg2+ on intracellular Ca2+ dynamic changes and thapsigargin-induced apoptosis in human cancer MCF7 cells. Mol Cell Biochem (2002) 0.80
Thapsigargin induces rapid, transient growth inhibition and c-fos expression followed by sustained growth stimulation in mouse keratinocyte cultures. J Invest Dermatol (1996) 0.80
[Clinical investigations of 6-azathymine: a thymine analog]. Cancer Res (1960) 0.80
ToP: a trend-of-disease-progression procedure works well for identifying cancer genes from multi-state cohort gene expression data for human colorectal cancer. PLoS One (2013) 0.79
A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug-resistant cell lines. Br J Cancer (1992) 0.79
Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. Phytother Res (2010) 0.79
Ginkgo May Sensitize Ovarian Cancer Cells to Cisplatin: Antiproliferative and Apoptosis-Inducing Effects of Ginkgolide B on Ovarian Cancer Cells. Integr Cancer Ther (2012) 0.78
Chronic lymphocytic leukaemia, synchronous small cell carcinoma and squamous neoplasia of the urinary bladder in a paraplegic man following long-term phenoxybenzamine therapy. Spinal Cord (2006) 0.78
Characterization of novel inhibitors of cyclin-dependent kinases. Biochem Biophys Res Commun (1999) 0.78
Ginkgo may prevent genetic-associated ovarian cancer risk: multiple biomarkers and anticancer pathways induced by ginkgolide B in BRCA1-mutant ovarian epithelial cells. Eur J Cancer Prev (2011) 0.78